PBPK Resources

Open Systems Pharmacology: PK-Sim® and MoBi® for PBPK modelling and quantitative systems pharmacology, with user forum, documentation and news.

Our models and tools:

• PBPK models on GitHub: our published PBPK models
• PBPK Model Portfolio: overview of our PBPK models
• PBPK Explorer: body composition for PBPK modelling
• DDGI-DSS: simulation of drug-drug-gene interactions with our PBPK models

Getting Started with PK-Sim: eight short videos that take you from installing PK-Sim to running your first simulation, using midazolam as the example. The series is also available as a YouTube playlist.

More videos are on our YouTube channel.

• Dette CMU, Marok FZ, Alberg V, et al. Parent-metabolite PBPK model of methotrexate to inform pediatric extrapolation, transporter-mediated drug–drug interactions, and renal impairment. Sci Rep. 2026;16:37244. doi:10.1038/s41598-026-77381-0
• Zaher O, Selzer D, Loer H, et al. Physiologically based pharmacokinetic modeling as a translational tool in forensic toxicology: from pig to human synthetic cannabinoid toxicokinetics using 5F-Cumyl-P7AICA and its major metabolite as a case study. Arch Toxicol. 2026. doi:10.1007/s00204-026-04613-7
• Hauß C, Feick D, Selzer D, et al. Physicochemical interactions between oral drug products: An integrated in vitro and PBPK modeling approach. Int J Pharm. 2026;704:127375. doi:10.1016/j.ijpharm.2026.127375
• Wu Y, Loer HLH, Zhang Y, et al. Development and verification of a physiologically based pharmacokinetic model of furmonertinib and its main metabolite for drug–drug interaction predictions. CPT Pharmacometrics Syst Pharmacol. 2025. doi:10.1002/psp4.70052
• Kovar C, Loer HLH, Rüdesheim S, et al. A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2024. doi:10.1002/psp4.13146
• Marok FZ, Wojtyniak JG, Selzer D, et al. Personalized chronomodulated 5-fluorouracil treatment: A physiologically-based pharmacokinetic precision dosing approach for optimizing cancer therapy. Clin Pharmacol Ther. 2024. doi:10.1002/cpt.3181
• Loer HLH, Kovar C, Rüdesheim S, et al. Physiologically based pharmacokinetic modeling of imatinib and N-desmethyl imatinib for drug-drug interaction predictions. CPT Pharmacometrics Syst Pharmacol. 2024. doi:10.1002/psp4.13127
• Fuhr LM, Marok FZ, Fuhr U, et al. Physiologically based pharmacokinetic modeling of bergamottin and 6,7-dihydroxybergamottin to describe CYP3A4 mediated grapefruit-drug interactions. Clin Pharmacol Ther. 2023;114(2):470-482. doi:10.1002/cpt.2968

All original publications